<?xml version="1.0" encoding="UTF-8"?>
<p>Control strains used for 
 <italic>in vitro</italic> evaluation were the CLSI reference strains, including 
 <italic>Candida albicans</italic> ATCC 2091, 
 <italic>C. glabrata</italic> CBS 138, 
 <italic>C. krusei</italic> ATCC 6258, 
 <italic>C. parapsilosis</italic> ATCC 22019 and 
 <italic>C. parapsilosis</italic> ATCC 90018. Additionally, numerous clinical isolates from the collection of EA1155 IICiMed were used: 
 <italic>C. albicans</italic> (
 <italic>n</italic> = 26), 
 <italic>C. glabrata</italic> (
 <italic>n</italic> = 12), 
 <italic>C. krusei</italic> (
 <italic>n</italic> = 14), 
 <italic>C. parapsilosis</italic> (
 <italic>n</italic> = 18) and 
 <italic>C. tropicalis</italic> (
 <italic>n</italic> = 6). The selected species are representative of the European epidemiology and therefore correspond to the five most prevalent species in the clinic settings
 <xref rid="CIT0024" ref-type="bibr">
  <sup>24</sup>
 </xref>. Strains were maintained and subcultured 24 h before used on Sabouraud’s agar slants.
</p>
